December 17, 2024 00:20 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
GRAP 4 restrictions reimposed in Delhi as air quality dips to 'severe' category | 39 ministers included in Devendra Fadnavis-led Maharashtra cabinet | People who raise questions on EVMs should show how they can be hacked: TMC trashes Congress claims | Bangladesh likely to hold national polls in late 2025 or early 2026, says Yunus in Victory Day speech | Constitution stood test of time: Nirmala Sitharaman in Rajya Sabha | PM Museum requests Rahul Gandhi to return Pandit Nehru's historical letters | Indian tabla maestro Zakir Hussain dies at 73 in San Francisco, confirms family | Kolkata woman strangled, beheaded and chopped into pieces for refusing brother-in-law's advances | Arvind Kejriwal, CM Atishi to contest Delhi polls from current constituencies | Atul Subhash suicide case: Wife Nikita, her mother and brother arrested
Sanofi, Regeneron announce positive Dupilumab Topline results from two phase 3 trials

Sanofi, Regeneron announce positive Dupilumab Topline results from two phase 3 trials

Apr 02, 2016, at 04:39 am

Kolkata/Paris, Apr 1 (IBNS) Sanofi and Regeneron Pharmaceuticals, Inc. announced that two placebo-controlled Phase 3 studies evaluating investigation dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD) met their primary endpoints.